<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815711</url>
  </required_header>
  <id_info>
    <org_study_id>2007H0002</org_study_id>
    <nct_id>NCT00815711</nct_id>
  </id_info>
  <brief_title>Idiopathic Pulmonary Fibrosis Registry for Future Studies</brief_title>
  <official_title>Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish a registry of patients for future studies of Inflammation in Interstitial Lung&#xD;
      Disease/Idiopathic Pulmonary Fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To establish a framework in which biologic samples and physiologic measures from patients&#xD;
      with IPF can be longitudinally collected and evaluated. Having a bank of samples that are&#xD;
      correlated with physiologic measures that follow patients through their course will allow the&#xD;
      following proposed studies as well as future investigations to be efficiently carried out.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2008</start_date>
  <completion_date type="Actual">June 10, 2015</completion_date>
  <primary_completion_date type="Actual">June 10, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Framework</measure>
    <time_frame>7 + years</time_frame>
    <description>To establish a framework in which biologic samples and physiologic measures from patients with IPF can be longitudinally collected and evaluated</description>
  </primary_outcome>
  <enrollment type="Actual">13</enrollment>
  <condition>Lung Disease, Interstitial</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood serum BAL fluid lung biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  any patient referred to the Interstitial Lund Disease clinic who is undergoing&#xD;
             evaluation and or treatment for a new diagnosis of ILD. This can include patients&#xD;
             referred for presumed pulmonary fibrosis/interstitial pneumonitis (IPF, UIP, NSIP),&#xD;
             sarcoidosis, hypersensitivity pneumonitis, cryptogenic organising pneumonia,&#xD;
             drug-induced, or other idiopathic ILDs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  inability to follow study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clay B Marsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 29, 2008</study_first_submitted>
  <study_first_submitted_qc>December 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2008</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IPF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

